AbbVie is our Top Pick globally followed by PFE and AZN (Top Pick in Europe). We also remain very positive on Roche (pipeline), and ZTS (M&A/ Bayer spinversion) as well as on LLY, for which we have updated our estimates in this note and increased our PT to $100. We remain cautious on ABT (lack of catalysts), GSK (-ve earnings momentum) and BMY (mid-term IO threats/ valuation).